$PSYGF News
Last published 4y ago
- 4y agoPSYGFPsyence Group Corporate UpdateGlobeNewswireHighlights: Partnership with CRO Clerkenwell Health to design and deliver Psyence's UK clinical trial progressing; exclusive licensing agreement with Filament Health Dr. Clive Ward-Able has been appointed as Medical Director, Head of Research & De
- 4y agoPSYGFPsyence Taps Another Pharma Exec to Drive its Clinical ProgramGlobeNewswireTORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG, OTCQB:PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce
- 4y agoFLHLFPSYGFPsyence and Filament Health Enter Into Exclusive Licensing Agreement for Natural Psilocybin ProductsGlobeNewswireVANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc (CSE:PSYG, OTCQB:PSYGF) ("Psyence"), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, and Filament Health Co
- 5y agoPSYGFPsyence Group Announces Commencement of Trading on OTCQB and DTC Eligibility of Common Shares in the United States Under the Ticker "PSYGF"GlobeNewswireTORONTO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG, OTCQB:PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce